Search Criteria: COVID-19 Studies;
C4671026: Study drugs for Children with COVID-19 in Children
(IRB#: IRB_00155069)
Nirmatrelvir and Ritonavir are study drugs for children with COVID-19. These study drugs are only approved by the federal drug administration (FDA) for adults. Research is needed to learn the effectiveness of the study drugs and find the best dose for children with COVID-19.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Paid
How COVID-19 has Impacted Secondary School Aged Students with Autism
(IRB#: IRB_00135759)
The purpose of this study is to explore the academic, psychological and social experiences of secondary school aged individuals with an autism spectrum disorder during COVID-19.
- All genders
- Over 7 years old
- Healthy Volunteers
- From Home
- Paid
LAU-7b: A Study Drug for People Hospitalized with COVID-19
(IRB#: IRB_00152353)
Peoples health with COVID-19 and other medical issues such as high blood pressure or existing lung disease may get worse over time and might need to go to the Intensive Care Unit. LAU-7b is a study drug for people with COVID-19 that also have other medical issues. Research is needed to know if the drug is safe and effective to improve peoples health. The information we learn may aid future patients.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Nintedanib: A Study Drug for COVID-19 Interstitial Lung Disease (ILD)
(IRB#: IRB_00148442)
Nintedanib is a study drug to slow the rate of lung scarring from interstitial lung disease (ILD), a lung injury caused by COVID-19. Scientists and doctors do not know the effectiveness of the treatment. Research is needed to learn if the drug may be approved and used to improve the health of people suffering from ILD.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Tocilizumab or TCQ: A Study Drug for Pediatric Patients with COVID-19
(IRB#: IRB_00150759)
Tocilizumab or TCQ is a study drug to help pediatric patients hospitalized with COVID-19. Research is needed to learn if it is safe and effective for these patients. The information we gain may aid futures patients.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Paid
Treating healthcare provider burnout using Psilocybin-Assisted Psychotherapy and Mindfulness-Based Stress Reduction
(IRB#: IRB_00152312)
Many healthcare providers on the frontlines of the SARS-CoV-2 pandemic felt burnt out and depressed. We want to see if mindfulness training helps with these feelings. We also want to see if psilocybin-assisted therapy helps with these feelings. The frontline healthcare providers who sign up will get mindfulness training for 8 weeks. Half of the providers will also get psilocybin-assisted therapy.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Unpaid
University of Utah Long Covid Registry
(IRB#: IRB_00140978)
Researchers at the University of Utah have established a registry to follow individuals who are experiencing prolonged symptoms after COVID-19 infection. We are interested in following people with "Long Covid" using in depth health surveys and optional blood draws to better understand this condition with the goal of ultimately developing clinical management strategies.
- All genders
- Over 18 years old
- Volunteers with special conditions
- From Home
- Unpaid